Trial Profile
A Phase 1 Study of DS-1001b in Patients with IDH1 Mutated Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Safusidenib (Primary)
- Indications Glioma
- Focus Adverse reactions; First in man
- 14 Feb 2023 Results assessing the safety, pharmacokinetics, pharmacodynamics, and efficacy of DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas published in the Neuro-Oncology
- 12 Mar 2021 Planned End Date changed from 1 Mar 2022 to 1 Mar 2026.
- 07 Sep 2020 According to an AnHeart Therapeutics media release, it has entered into license agreements with Daiichi Sankyo Company, to acquire rights to DS-1001 novel clinical stage oncology candidates.AnHeart will develop this compound for glioma and potentially other indications including acute myeloid leukemia (AML) and cholangiocarcinoma globally, except in Japan where Daiichi Sankyo will retain exclusive rights.